-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Nirsevimab
| Category | Respiratory syncytial Virus (RSV) |
| CAS | 1989556-22-0 |
| Description | Nirsevimab is a monoclonal antibody developed for the prevention of respiratory syncytial virus (RSV) infections in infants. Nirsevimab specifically targets the respiratory syncytial virus (RSV) fusion (F) protein, which is essential for viral entry and replication in respiratory cells. By binding to the F protein, nirsevimab prevents RSV from infecting cells and replicating, thereby reducing the likelihood of severe respiratory illness. It is being investigated for the prevention of RSV infection in infants, particularly those at high risk of severe disease. RSV is a common respiratory virus that can cause serious illness, especially in premature infants and those with certain medical conditions. |
Product Information
| Synonyms | MEDI8897 |
| Appearance | Liquid |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
